Patient and Health Care Provider Perspectives on Long Acting Injectable Antipsychotics in Schizophrenia and the Introduction of Olanzapine Long-Acting Injection

Patient and Health Care Provider Perspectives on Long Acting Injectable Antipsychotics in Schizophrenia and the Introduction of Olanzapine Long-Acting Injection

Olanzapine long acting injection has joined risperidone and paliperidone as the second generation long acting antipsychotic injection options for treatment of patients with schizophrenia. Long acting injections are important alternatives to oral medications for patients who have difficulty adhering...

Full description

Bibliographic Details
Main Authors:	Wehring, Heidi J., Thedford, Sheryl, Koola, Maju, Kelly, Deanna L.
Format:	Online
Language:	English
Published:	Libertas Academica 2011
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3535454/

Similar Items

Long-Acting Injectable Antipsychotics in First-Episode Schizophrenia
by: Parellada, Eduard, et al.
Published: (2012)

Long-acting Injectable Antipsychotics in First-episode Schizophrenia
by: Jeong, Hyun-Ghang, et al.
Published: (2013)

The Use of Long-Acting Injectable Antipsychotic Therapy for Schizophrenia
by: Jason Jiang, et al.
Published: (2018-09-01)

Pharmacokinetics of olanzapine long-acting injection: the clinical perspective
by: Heres, Stephan, et al.
Published: (2014)

Switching to olanzapine long-acting injection from either oral olanzapine or any other antipsychotic: comparative post hoc analyses
by: Ciudad, Antonio, et al.
Published: (2013)

Long-Acting Injectable Antipsychotics for First-Episode Schizophrenia: The Pros and Cons
by: Kim, Borah, et al.
Published: (2012)

Clinical Decision-Making in the Treatment of Schizophrenia: Focus on Long-Acting Injectable Antipsychotics
by: Samalin, Ludovic, et al.
Published: (2016)

Clinical benefits and impact of early use of long‐acting injectable antipsychotics for schizophrenia
by: Stevens, Georgia L., et al.
Published: (2015)

A pooled analysis of injection site-related adverse events in patients with schizophrenia treated with olanzapine long-acting injection
by: Atkins, Susan, et al.
Published: (2014)

Schizophrenia symptoms and functioning in patients receiving long-term treatment with olanzapine long-acting injection formulation: a pooled analysis
by: Peuskens, Joseph, et al.
Published: (2012)

Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection
by: Ascher-Svanum, Haya, et al.
Published: (2014)

Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness
by: Llorca, Pierre Michel, et al.
Published: (2013)

Role of Long-Acting Injectable Second-Generation Antipsychotics in the Treatment of First-Episode Schizophrenia: A Clinical Perspective
by: Přikryl, Radovan, et al.
Published: (2012)

Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophrenia
by: Potkin, Steven, et al.
Published: (2013)

Switching from risperidone long-acting injectable to paliperidone long-acting injectable or oral antipsychotics: analysis of a Medicaid claims database
by: Voss, Erica A., et al.
Published: (2015)

Olanzapine long-acting injection: a review of first experiences of post-injection delirium/sedation syndrome in routine clinical practice
by: Bushe, Chris J, et al.
Published: (2015)

Treatment-completion rates with olanzapine long-acting injection versus risperidone long-acting injection in a 12-month, open-label treatment of schizophrenia: indirect, exploratory comparisons
by: Ascher-Svanum, Haya, et al.
Published: (2012)

Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain – a cost-effectiveness comparison
by: Dilla, Tatiana, et al.
Published: (2014)

Health-related quality of life advantage of long-acting injectable antipsychotic treatment for schizophrenia: a time trade-off study
by: Osborne, Richard H, et al.
Published: (2012)

Treatment Adherence with Early Prescription of Long-Acting Injectable Antipsychotics in Recent-Onset Schizophrenia
by: Viala, Annie, et al.
Published: (2012)

Oral versus Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Special Populations at Risk for Treatment Nonadherence: A Systematic Review
by: Zhornitsky, Simon, et al.
Published: (2012)

Risperidone long-acting injection in Schizophrenia Spectrum Illnesses compared to first generation depot antipsychotics in an outpatient setting in Canada
by: Lammers, Laura, et al.
Published: (2013)

Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia
by: Kaplan, Gabriel, et al.
Published: (2013)

Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics
by: Alphs, Larry, et al.
Published: (2013)

Long-acting injectable versus daily oral antipsychotic treatment trials in schizophrenia: pragmatic versus explanatory study designs
by: Bossie, Cynthia A., et al.
Published: (2015)

Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France
by: Druais, Sylvain, et al.
Published: (2016)

Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life
by: Montemagni, Cristiana, et al.
Published: (2016)

Long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia
by: Louzã, Mário Rodrigues, et al.
Published: (2011)

Risperidone Long-Acting Injection: Safety and Efficacy in Elderly Patients with Schizophrenia
by: Catalán, Rosa, et al.
Published: (2011)

Use of Aripiprazole Long Acting Injection in Negative Symptoms of Schizophrenia
by: James, Suneeta, et al.
Published: (2016)

IVIVC from Long Acting Olanzapine Microspheres
by: D'Souza, Susan, et al.
Published: (2014)

Effects of long-acting injectable antipsychotics versus oral antipsychotics on autonomic nervous system activity in schizophrenic patients
by: Suda A, et al.
Published: (2018-09-01)

Clinical outcomes with olanzapine long-acting injection: impact of the 3-hour observation period on patient satisfaction and well-being
by: Anand, Ernie, et al.
Published: (2016)

Within-drug benefit-risk evaluation of olanzapine long-acting injection at one and two years of treatment
by: Detke, Holland C, et al.
Published: (2014)

Long-acting injectable antiretrovirals for HIV treatment and prevention
by: Spreen, William R., et al.
Published: (2013)

Early response predicts subsequent response to olanzapine long-acting injection in a randomized, double-blind clinical trial of treatment for schizophrenia
by: Ascher-Svanum, Haya, et al.
Published: (2011)

Efficacy of olanzapine long-acting injection in patients with acutely exacerbated schizophrenia: an insight from effect size comparison with historical oral data
by: Detke, Holland C, et al.
Published: (2012)

Baseline characteristics and hospitalizations in patients with schizophrenia receiving olanzapine long-acting injection: an interim analysis from a non-interventional, prospective observational safety study
by: Jones, Meghan E., et al.
Published: (2015)

Proposing the use of partial AUC as an adjunctive measure in establishing bioequivalence between deltoid and gluteal administration of long-acting injectable antipsychotics
by: Lee, Lik Hang N., et al.
Published: (2016)

A case series on the use of atypical long acting injectable as first-line antipsychotic treatment in Malaysia: who benefits and how?
by: Mohd Aizat bin Mohamad Nor
Published: (2013)